IPO
Filter News
Found 17,233 articles
-
Haemonetics 4th Quarter Fiscal Year 2021 Earnings Release Available on Investor Relations Website
5/13/2021
Haemonetics Corporation announced that financial results for its fourth quarter fiscal 2021, which ended April 3, 2021, are available on its Investor Relations website.
-
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
5/13/2021
Commercial Activities Advancing for Upcoming Launch of LibmeldyTM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany
-
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
5/13/2021
Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease
-
Sotera Health Reports First-Quarter 2021 Results
5/13/2021
Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced financial results for the three months ended March 31, 2021.
-
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
5/13/2021
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced first quarter 2021 financial results and provided an update on the cytisinicline clinical development program.
-
TELA Bio Announces First Quarter 2021 Financial Results
5/13/2021
TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, reported financial results for the first quarter ended March 31, 2021.
-
Procaps Group Reports Record First Quarter 2021 Financial Results
5/13/2021
First Quarter 2021 Net Revenues Increased 36% to $80.5 Million Year-Over-Year with Adjusted EBITDA Up 103% Year-Over-Year
-
Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results
5/13/2021
Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021
-
TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
5/13/2021
TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, reported financial results for the first quarter ended March 31, 2021, as well as provided a business update on recent corporate and clinical developments.
-
Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/13/2021
Viveve Medical, Inc., a medical technology company focused on women's intimate health, reported financial results for the quarter ended March 31, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.
-
Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights
5/13/2021
Phase 2 trial initiation for Parkinson’s disease dementia program and IND submission for neuropsychiatric program planned by end of 2021
-
Movano Inc. Provides Business Update and Reports First Quarter 2021 Financial Results
5/13/2021
Movano Inc., a health technology company designing devices that empower individuals to optimize their health in order to help prevent and better manage chronic diseases, reported financial results for the three months ending March 31, 2021 and provided a business update.
-
Savara Reports First Quarter 2021 Financial Results and Provides Business Update
5/13/2021
Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2021 and provided a business update.
-
BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
5/13/2021
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, published its fourth quarter and full year financial results for the year ended December 31, 2020 and provided a business update.
-
PolarityTE Reports First Quarter Results and Provides Business Update
5/13/2021
PolarityTE, Inc., a biotechnology company developing regenerative tissue products and biomaterials, provided a business update and reported financial results for the first quarter ended March 31, 2021.
-
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
5/13/2021
4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational highlights.
-
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/13/2021
Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team
-
Marrone Bio Innovations, Inc. Reports First-Quarter 2021 Financial Results
5/13/2021
Marrone Bio Innovations, Inc. has provided its financial results for the first quarter ended March 31, 2021.
-
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
5/13/2021
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the first quarter ended March 31, 2021.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 13, 2021
5/13/2021
CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.